Myeloid-derived suppressor cells: A double-edged sword?

International Journal of Experimental Pathology

Volumn 92, Issue 2, 2011, Pages 73-78

  Pastuła, Agnieszka ^a   Marcinkiewicz, Janusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antitumour immunity; Immunoregulatory properties; Myeloid derived suppressor cells

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; CYCLOPHOSPHAMIDE; N(G) METHYLARGININE;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; BREAST ADENOCARCINOMA; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CELL POPULATION; COLON ADENOCARCINOMA; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; EHRLICH ASCITES TUMOR; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOMA; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OSTEOMYELITIS; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; TUMOR IMMUNITY;

ANIMALS; BONE MARROW CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNIZATION; MICE; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 79952794385     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2010.00754.x     Document Type: Review

References (59)

1. Almand B., Clark J.I., Nikitina E. et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689.
2. Angulo I., de las Heras F.G., García-Bustos J.F., Gargallo D., Muñoz-Fernández M.A., Fresno M. (2000a) Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95, 212-220.
3. Angulo I., Rullas J., Campillo J.A. et al. (2000b) Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-gamma stimulation through a mechanism dependent on endogenous TNF-alpha and IL-1alpha. Eur. J. Immunol. 30, 1263-1271.
4. Avogadri F., Martinoli C., Petrovska L. et al. (2005) Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 65, 3920-3927.
5. Bereta M., Hayhurst A., Gajda M. et al. (2007) Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. Vaccine 25, 4183-4192.
6. Bronte V., Zanovello P. (2005) Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641-654. Review.
7. Bronte V., Apolloni E., Cabrelle A. et al. (2000) Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96, 3838-3846.
8. Bunt S.K., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176, 284-290.
9. Caquard M., Ferret-Bernard S., Haurogné K. et al. (2010) Diabetes acceleration by cyclophosphamide in the non-obese diabetic mouse is associated with differentiation of immunosuppressive monocytes into immunostimulatory cells. Immunol. Lett. 129, 85-93.
10. Chen G., Wei D.P., Jia L.J. et al. (2009) Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity. Cancer Sci. 100, 2437-2443.
11. Cripps J.G., Wang J., Maria A., Blumenthal I., Gorham J.D. (2010) Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver. Hepatology 52, 1350-1359.
12. Dardalhon V., Anderson A.C., Karman J. et al. (2010) Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J. Immunol. 185, 1383-1392.
13. De Santo C., Salio M., Masri S.H. et al. (2008) Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 118, 4036-4048.
14. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59.
15. Ezernitchi A.V., Vaknin I., Cohen-Daniel L. et al. (2006) TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177, 4763-4772.
16. Fridlender Z.G., Sun J., Kim S. et al. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16, 183-194.
17. Gabrilovich D.I., Nagaraj S. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174. Review.
18. Gómez-García L., López-Marín L.M., Saavedra R., Reyes J.L., Rodríguez-Sosa M., Terrazas L.I. (2005) Intact glycans from cestode antigens are involved in innate activation of myeloid suppressor cells. Parasite Immunol. 27, 395-405.
19. Goñi O., Alcaide P., Fresno M. (2002) Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+)immature myeloid suppressor cells. Int. Immunol. 14, 1125-1134.
20. Greifenberg V., Ribechini E., Rössner S., Lutz M.B. (2009) Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 39, 2865-2876.
21. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., Colombo M.P. (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437-3446.
22. Hoechst B., Voigtlaender T., Ormandy L. et al. (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50, 799-807.
23. Holda J.H., Maier T., Claman H.N. (1985) Murine graft-versus-host disease across minor barriers: immunosuppressive aspects of natural suppressor cells. Immunol. Rev. 88, 87-105. Review.
24. Hu C.E., Gan J., Zhang R.D., Cheng Y.R., Huang G.J. (2010) Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand. J. Gastroenterol. in press.
25. Huang B., Pan P.Y., Li Q. et al. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-1131.
26. Iwata Y., Furuichi K., Kitagawa K. et al. (2010) Involvement of CD11b(+) GR-1 (low) cells in autoimmune disorder in MRL-Fas (lpr) mouse. Clin. Exp. Nephrol. 14, 411-417.
27. Jordan M.B., Mills D.M., Kappler J., Marrack P., Cambier J.C. (2004) Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304, 1808-1810.
28. Ko H.J., Lee J.M., Kim Y.J., Kim Y.S., Lee K.A., Kang C.Y. (2009) Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J. Immunol. 182, 1818-1828.
29. Kusmartsev S., Nefedova Y., Yoder D., Gabrilovich D.I. (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989-999.
30. Li H., Han Y., Guo Q., Zhang M., Cao X. (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182, 240-249.
31. Liu C., Yu S., Kappes J. et al. (2007) Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109, 4336-4342.
32. Liu C.Y., Wang Y.M., Wang C.L. et al. (2009) Population alterations of L: - arginase - and inducible nitric oxide synthase-expressed CD11b(+)/CD14 (-)/CD15 (+)/CD33 (+) myeloid-derived suppressor cells and CD8 (+) T lymphocytes in patients with advanced-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 136, 35-45.
33. Makarenkova V.P., Bansal V., Matta B.M., Perez L.A., Ochoa J.B. (2006) CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176, 2085-2094.
34. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677-686. Review.
35. Mazzoni A., Bronte V., Visintin A. et al. (2002) Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168, 689-695.
36. McCarthy E.F. (2006) The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 26, 154-158.
37. Mocellin S., Bronte V., Nitti D. (2007) Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med. Res. Rev. 27, 317-352. Review.
38. Nagaraj S., Gabrilovich D.I. (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 68, 2561-2563. Review.
39. Nagaraj S., Schrum A.G., Cho H.I., Celis E., Gabrilovich D.I. (2010) Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184, 3106-3116.
40. Narita Y., Wakita D., Ohkur T., Chamoto K., Nishimura T. (2009) Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed. Res. 30, 7-15.
41. Nausch N., Galani I.E., Schlecker E., Cerwenka A. (2008) Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood 112, 4080-4089.
42. Pak A.S., Ip G., Wright M.A., Young M.R. (1995) Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res. 55, 885-890.
43. Pawelek J.M., Low K.B., Bermudes D. (1997) Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57, 4537-4544.
44. Peláez B., Campillo J.A., López-Asenjo J.A., Subiza J.L. (2001) Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J. Immunol. 166, 6608-6615.
45. Ribechini E., Greifenberg V., Sandwick S., Lutz M.B. (2010) Subsets, expansion and activation of myeloid-derived suppressor cells. Med. Microbiol. Immunol. 199, 273-281.
46. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., Ostrand-Rosenberg S. (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179, 977-983.
47. Sottnik J.L., U'Ren L.W., Thamm D.H., Withrow S.J., Dow S.W. (2010) Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. Cancer Immunol. Immunother. 59, 367-378.
48. Srivastava M.K., Bosch J.J., Thompson J.A., Ksander B.R., Edelman M.J., Ostrand-Rosenberg S. (2008) Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol. Immunother. 57, 1493-1504.
49. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg S. (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70, 68-77.
50. Stout R.D., Suttles J. (2004) Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J. Leukoc. Biol. 76, 509-513. Review.
51. Strober S. (1984) Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships. Annu. Rev. Immunol. 2, 219-237. Review.
52. Sugiura K., Inaba M., Ogata H. et al. (1990) Inhibition of tumor cell proliferation by natural suppressor cells present in murine bone marrow. Cancer Res. 50, 2582-2586.
53. Talmadge J.E. (2007) Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 13, 5243-5248. Review.
54. Terabe M., Matsui S., Park J.M. et al. (2003) Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198, 1741-1752.
55. Tomihara K., Guo M., Shin T. et al. (2010) Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J. Immunol. 184, 6151-6160.
56. Umansky V., Schirrmacher V. (2001) Nitric oxide-induced apoptosis in tumor cells. Adv. Cancer Res. 82, 107-131. Review.
57. Wang H., MacNaughton W.K. (2005) Overexpressed beta-catenin blocks nitric oxide-induced apoptosis in colonic cancer cells. Cancer Res. 65, 8604-8607.
58. Watanabe S., Deguchi K., Zheng R. et al. (2008) Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J. Immunol. 181, 3291-3300.
59. Zhu B., Bando Y., Xiao S. et al. (2007) CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179, 5228-5237.